MyFinsight
Home
Blog
About
Contact
Download
Download image
Property, plant and
equipment, gross
$380,000K
Prepaid expenses and
other assets
$61,000K
Inventory
$52,000K
Accounts receivable, net
$158,000K
Marketable securities
$259,000K
Cash and cash
equivalents
$421,000K
Other assets
$60,000K
Goodwill
$44,000K
Intangible assets, net
$176,000K
Marketable securities
$57,000K
Property, plant, and
equipment, net
$244,000K
Total current assets
$951,000K
Less accumulated
depreciation
$136,000K
Total assets
$1,532,000K
Accumulated deficit
-$4,532,000K
Treasury stock, at cost,
0.2 shares in 2025...
$8,000K
Total liabilities,
noncontrolling interest and...
$1,532,000K
Total stockholders'
equity (deficit)
-$80,000K
Accumulated other
comprehensive income (loss)
$1,000K
Additional paid-in capital
$4,451,000K
Deferred compensation
obligation
$8,000K
Noncontrolling interest
$7,000K
Total liabilities
$1,605,000K
Other liabilities
$20,000K
Liabilities for sales of
future royalties
$1,147,000K
Deferred tax liabilities
$30,000K
Lease liabilities
$24,000K
Total current
liabilities
$384,000K
Other liabilities
$7,000K
Liabilities for sales of
future royalties
$69,000K
Lease liabilities
$12,000K
Accrued liabilities
$265,000K
Accounts payable
$31,000K
Back
Back
Balance Sheet
source: myfinsight.com
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)